macrolid
enjoy
continu
use
year
increasingli
usedfor
treatment
ofr
piratori
tract
infect
newer
macrolid
introduc
show
improv
ab
orption
oral
administr
better
gastrointestin
toler
deliveri
increas
amount
ofdrug
infect
ite
macrolid
commonli
use
communityacquir
pneumonia
ell
atyp
pneumonia
legionello
newer
macrolid
compar
studi
shown
effect
convent
therapi
treat
acut
otiti
media
acut
sinus
acut
pharyng
low
incid
sideeffect
holvev
dose
simplifi
uniqu
pharmacokinet
properti
limit
use
macrolid
respiratori
infect
includ
rather
margin
activ
sever
case
ofhaemophilu
influenza
infect
lack
activ
kleb
iella
coliform
preclud
lise
singl
agent
therapi
pneumonia
patient
signific
underli
diseas
elderli
develop
resist
treptococci
taphylococci
macrolid
name
macrocycl
lactos
nucleu
contain
tabl
erythromycin
first
agent
ofthi
class
describ
deriv
strain
streptomyc
erythreu
discov
soil
sampl
philippin
macrolid
wide
use
last
four
decad
mainli
outpati
respiratori
tract
infect
recent
year
use
clinic
practic
becom
even
extens
renew
interest
macrolid
antibiot
sever
caus
valu
treatment
lower
respiratori
tract
infect
increasingli
appreci
sinc
antibacteri
spectrum
match
almost
exactli
requir
therapi
pulmonari
infect
caus
recent
recogn
pathogen
legionella
spp
chlamydia
pneumonia
c
trachomati
molecul
develop
overcom
disadvantag
associ
erythromycin
irregular
limit
absorpt
oral
administr
frequent
advers
gastrointestin
sideeffect
addit
newer
agent
assur
increas
amount
drug
infect
tissu
recent
introduc
includ
particular
macrolid
roxithromycin
dirithromycin
flurithromycin
clarithromycin
ismemb
azithromycin
result
insert
methylsubstitut
nitrogen
erythromycin
molecul
produc
new
class
macrolid
azalid
macrolid
broadspectrum
antibiot
activ
gramposit
gramneg
speci
tabl
antimicrobi
activ
due
bind
macrolid
molecul
ribosom
subunit
effect
block
ribosom
p
site
result
inhibit
rnadepend
protein
synthesi
due
differ
ribosom
structur
bind
occur
eucaryot
cell
account
low
toxic
ofmacroiid
human
ofparticular
interest
context
respiratori
tract
infect
therapi
fact
macrolid
exhibit
consist
activ
atyp
bacteria
frequent
involv
pneumonia
eg
mycoplasma
pneumonia
chlamydia
spp
whereaslactam
aminoglycosid
ineffect
macrolid
also
possess
excel
potenc
legionella
spp
bordetella
pertussi
corynebacterium
diphtheria
well
certain
antimycobacteri
activ
help
context
recent
increas
preval
multipleresist
problem
diseas
erythromycin
shown
bactericid
toward
group
streptococci
streptococcu
pneumonia
haemophilu
infiuenza
high
concentr
postantibiot
effect
demonstr
speci
contrast
antistaphylococc
effect
essenti
bacteriostat
postantibiot
effect
shown
prolong
exposur
high
concentr
vitro
activ
macroiid
exhibit
certain
differ
variou
compound
compar
gener
macrolid
activ
streptococci
b
pertussi
azithromycin
ismemb
azaiid
turn
activ
macrolid
clarithromycin
activ
compound
streptococcu
pyogen
pneumococci
corynebacterium
spp
azithromycin
exhibit
greatli
enhanc
potenc
eightfold
gramneg
speci
includ
h
infiuenza
moraxella
catarrhali
campylobact
jejuni
enterobacteriacea
probabl
result
insert
second
basic
site
proton
macrocycl
nucleu
improv
outer
membran
clarithromycin
yield
similar
minim
inhibitori
concentr
mic
h
injluenza
erythromycin
metabol
vivo
lead
product
metabolit
littl
activ
parent
compound
gener
addit
effect
resist
macrolid
may
result
reduc
permeabl
enterobacteriacea
drug
inactiv
notabl
staphylococcu
aureu
escherichia
coli
importantli
alter
target
site
last
mechan
involv
demethyl
adenin
residu
ribosom
rna
lead
reduct
affin
antibiot
fraction
ribosom
result
activ
macrolid
lincosamid
streptogramin
b
socal
ml
b
phenotyp
affect
alter
induc
case
resist
appar
dissoci
macrolid
clearli
inact
wherea
mic
macrolid
less
clinic
efficaci
macrolid
infect
caus
strain
possess
induc
ml
b
phenotyp
howev
remain
solidli
document
author
feel
would
prefer
avoid
use
macrolid
case
ml
b
resist
also
constitut
clear
cut
resist
antibiot
ofth
group
ml
b
resist
shown
mani
bacteri
speci
includ
staphylococci
streptococci
c
diphtheria
le
gionella
spp
erythromycin
resist
methylas
gene
erm
respons
ml
b
phenotyp
locat
plasmid
transposon
chromosom
preval
resist
macrolid
show
great
geograph
variat
resist
methicillinsuscept
aureu
rang
commun
isol
frequent
suscept
hospit
isol
major
methicillinresist
staphylococci
resist
macrolid
preval
erythromycin
resist
pneumococci
also
variabl
tend
increas
recent
year
percentag
resist
seem
peak
south
africa
reach
one
report
pocket
high
incid
report
franc
belgium
spain
mani
area
resist
report
lower
pneumococc
isol
especi
troublesom
multipl
resist
affect
practic
drug
avail
except
vancomycin
resist
pyogen
gener
less
part
world
notabl
except
japan
preval
exceed
report
resist
legionella
spp
mycoplasma
infrequ
remain
rare
c
diphtheria
macrolid
administ
oral
improv
acid
stabil
greater
oral
bioavail
obtain
newer
compound
compar
erythromycin
excel
tissu
penetr
pharmacokinet
hallmark
macrolid
penetr
well
host
cell
particularli
phagocyt
within
cell
macrolid
slowli
egress
consequ
tissu
plasma
antibiot
ratio
well
lover
complet
time
cours
follow
ingest
high
macrolid
concentr
found
tissu
bodi
fluid
except
cerebrospin
fluid
tissu
plasma
halfliv
prolong
tabl
appar
volum
distribut
rel
larg
practic
term
uniqu
pharmacokinet
profil
allow
simplifi
dose
schedul
possibl
daili
administr
roxithromycin
dirithromycin
azithromycin
tissu
specif
depend
compound
appear
especi
remark
case
azithromycin
featur
thought
due
insert
second
nitrogen
capabl
proton
molecul
oral
administr
azithromycin
produc
rel
low
plasma
concentr
number
anim
model
local
infect
demonstr
efficaci
azithromycin
correl
extravascular
pharmacokinet
blood
concentr
regard
respiratori
tract
infect
macrolid
assur
high
concentr
correspond
tissu
bodi
fluid
includ
tonsil
sputum
bronchial
secret
middl
ear
fluid
nasal
bronchial
mucosa
epitheli
alveolar
line
fluid
alveolar
macrophag
highest
lung
concentr
macrolid
occur
tabl
sinc
macrolid
often
use
ambulatori
patient
mild
moder
sever
respiratori
tract
infect
safeti
profil
extrem
import
notabl
guarante
good
complianc
gener
macrolid
extens
use
last
four
decad
littl
seriou
associ
toxic
erythromycin
use
pregnant
woman
gestat
stage
erythromycin
howev
gener
rapid
increas
gastric
upper
intestin
motil
administ
either
oral
intraven
rout
produc
seriou
discomfort
patient
high
incid
vomit
pharmacolog
ef
tabl
fect
thought
relat
intramolecular
cycliz
drug
inhibit
modif
ofth
function
group
particip
degrad
reaction
modif
keton
group
produc
exampl
deriv
includ
macrolid
azithromycin
roxithromycin
dirithromycin
less
prone
intramolecular
cycliz
creat
fewer
gastrointestin
effect
alter
alkyl
hydroxyl
group
produc
benefici
effect
alkyl
deriv
clarithromycin
exampl
also
associ
fewer
gastrointestin
effect
erythromycin
stearat
consequ
improv
absorpt
oral
administr
abil
assur
increas
amount
drug
site
infect
greater
gastrointestin
toler
like
newer
macrolid
progress
replac
erythromycin
pharyng
one
common
diseas
treat
gener
practition
approxim
ofal
case
ofpharyng
due
pyogen
antibiot
therapi
streptococc
pharyng
import
prevent
suppur
complic
notabl
otiti
reduct
risk
acut
rheumat
fever
gold
standard
treat
diseas
cours
ofan
oral
penicillin
poor
area
singl
intramuscular
inject
x
iu
benzathin
penicillin
problem
howev
associ
schedul
possibl
seriou
allerg
reaction
need
oral
administr
everi
h
pain
inject
high
incid
therapeut
failur
manifest
recurr
symptomat
ill
altern
cours
erythromycin
tradit
use
treat
streptococc
pharyng
patient
allerg
penicillin
newer
macrolid
may
howev
challeng
tradit
regimen
due
attract
pharmacokinet
properti
allow
simplifi
dose
excel
toler
sever
studi
shown
drug
like
josamycin
roxithromycin
azithromycin
efficaci
better
toler
tradit
compar
tabl
studi
newer
regimen
simplifi
may
led
better
patient
complianc
regard
efficaci
obtain
cours
azithromycin
especi
impress
acut
otiti
media
extrem
frequent
ill
children
peak
first
year
life
may
gener
seriou
sequela
properli
tabl
treat
microbiolog
otiti
media
document
cultur
middl
ear
effus
obtain
needl
aspir
four
lead
caus
pneumonia
h
injluenza
pyogen
catarrhali
repres
main
target
antimicrobi
therapi
amoxycillin
ampicillin
still
drug
choic
mani
geograph
area
emerg
oflactamaseproducingh
injluenza
catarrhali
may
lead
altern
prefer
amoxycillindavulan
cotrimoxazol
trimethoprimsulphamethoxazol
erythromycin
also
use
notabl
children
allergi
penicillin
margin
activ
h
injluenza
led
recommend
use
combin
sulphonamid
newer
macrolid
like
roxithromycin
dirithromycin
flurithromycin
possess
potenc
h
injluenza
erythromycin
higher
tissu
specif
may
creat
therapeut
advantag
still
need
firmli
establish
addit
effect
metabolit
greater
vitro
potenc
azithromycin
h
injluenza
repres
potenti
advantag
antibiot
treatment
otiti
media
due
speci
vs
similar
vs
signific
differ
level
p
bsignific
differ
level
p
newer
macrolid
gener
effect
convent
therapi
treat
acut
otiti
media
sometim
associ
lower
incid
sideeffect
furthermor
dose
schedul
simpler
convent
therapi
especi
case
azithromycin
one
oral
dose
daili
day
macrolid
recent
studi
tend
reduc
therapeut
regimen
cours
acut
sinus
usual
complic
viral
infect
upper
respiratori
tract
allerg
rhiniti
associ
dental
infect
potenti
sever
diseas
lead
mening
intracrani
abscess
bacteri
speci
often
respons
acut
sinus
includ
pneumonia
main
agent
h
injluenza
variou
anaerob
bacteria
belong
oral
flora
aureu
pyogen
catarrhali
also
implic
efficaci
antimicrobi
therapi
well
establish
diseas
convent
includ
drug
use
treat
otiti
media
signific
efficaci
obtain
use
macrolid
classic
studi
shown
patient
sinus
due
h
injluenza
respond
slowli
therapi
erythromycin
streptococc
sinus
recent
therefor
rel
poor
activ
h
injluenza
justifi
macrolid
consid
firstlin
drug
sinus
newer
compound
ensur
improv
penetr
appropri
tissu
fluid
may
revers
trend
illustr
statement
clarithromycin
found
effect
well
toler
amoxycillin
treatment
acut
sinus
azithromycin
day
yield
similar
result
clarithromycin
given
day
although
pneumonia
longer
regard
captain
ofth
men
ofdeath
diseas
remain
common
caus
ofinfectionrel
mortal
develop
countri
multipl
microbiolog
caus
ofpneumonia
sinc
exact
aetiolog
difficult
determin
mani
case
physician
must
use
manag
strategi
reli
precis
diagnosi
case
macrolid
part
strategi
sever
reason
drug
first
choic
mycoplasma
pneumonia
infect
main
bacteri
caus
socal
atyp
pneumonia
erythromycin
also
establish
standard
therapi
legionellosi
often
recommend
altern
therapi
pneumococc
pneumonia
notabl
patient
allerg
penicillin
macrolid
notlactam
activ
c
trachomati
result
pneumonia
infant
use
altern
tetracyclin
treatment
chlamydia
psittaci
infect
addit
macrolid
probabl
effect
newli
recogn
infect
caus
c
pneumonia
erythromycin
deriv
therefor
recommend
empir
therapi
communityacquir
pneumonia
normal
host
especi
clinic
background
correspond
virallik
ill
legionnair
diseas
suspect
proven
case
alac
tam
ampicillin
amoxycillinclavulan
combin
macrolid
complic
aris
certain
patient
group
eg
patient
advanc
age
especi
stay
nurs
home
underli
diseas
chang
aetiolog
consider
case
gramneg
bacteria
includ
klebsiella
pneumonia
h
injluenza
even
pseudomona
aeruginosa
becom
signific
risk
macroiid
recommend
addit
patient
clinic
sign
symptom
highli
suggest
pneumococc
pneumonia
penicillin
g
use
provid
patient
allerg
drug
recent
commonli
use
macrolid
communityacquir
pneumonia
erythromycin
studi
seem
indic
newer
macrolid
would
prefer
term
toler
eas
administr
although
similar
term
efficaci
roxithromycin
clarithromycin
maximum
durat
treatment
perform
equal
well
erythromycin
clarithromycin
day
azithromycin
day
washton
h
person
commun
major
acut
bronchiti
case
caus
respiratori
virus
rhinoviru
coronaviru
influenza
adenoviru
valu
ofantibiot
uncertain
small
proport
case
howev
bacteri
aetiolog
includ
pneumonia
b
pertussi
c
pneumonia
macrolid
indic
sever
mycoplasma
infect
earli
studi
indic
cough
begun
macrolid
alter
cours
diseas
given
earli
may
favour
effect
pertussi
macrolid
use
success
chemoprophylaxi
asymptomat
contact
case
c
pneumonia
infect
macrolid
yet
formal
evalu
pathogenesi
acut
exacerb
chronic
bronchiti
ecb
remain
unclear
mani
respect
role
bacteri
infect
controversi
chronic
colon
airway
unencapsul
strain
h
injluenza
pneumonia
catarrhali
frequent
role
bacteria
genesi
aecb
debat
pneumonia
anoth
possibl
caus
despit
obscur
background
antibiot
often
use
aecb
felt
may
improv
symptom
although
overal
benefit
unknown
erythromycin
macrolid
repres
possibl
choic
difficult
context
notabl
antimycoplasm
efficaci
patient
sever
respiratori
infect
blood
cultur
frequent
posit
cerebrospin
fluid
infect
especi
pneumonia
h
injluenza
infect
sinc
macrolid
poorli
penetr
cerebrospin
fluid
probabl
advis
use
singl
antimicrobi
agent
case
cours
observ
valid
legionellosi
extrem
sever
rare
complic
mening
macrolid
recommend
sever
staphylococc
infect
due
limit
bactericid
potenc
specif
h
influenza
infect
ofth
studi
present
describ
empir
therapi
respiratori
infect
patient
h
injluenza
formal
recogn
highli
suspect
invas
pathogen
eg
acut
epiglott
young
child
gener
macrolid
possess
margin
potenc
h
influenza
mic
typic
mgl
thu
recommend
contrast
piactam
quinolon
activ
good
clinic
record
set
multipl
studi
howev
involv
use
macrolid
especi
newer
compound
variou
respiratori
tract
infect
includ
diseas
h
injluenza
recogn
pathogen
respons
initi
therapi
shown
good
efficaci
use
macrolid
empir
antimicrobi
therapi
assur
accept
coverag
h
injluenza
infect
metabolit
overal
azithromycin
typic
mic
mgl
possess
improv
activ
h
injluenza
compar
drug
group
present
consid
clinic
studi
specif
address
problem
requir
definit
opinion
clinic
benefit
enhanc
potenc
macrolid
chemoprophylaxi
respiratori
tract
infect
discuss
macrolid
success
use
prevent
whoop
cough
erythromycin
drug
choic
erad
c
diphtheria
studi
efficaci
macrolid
n
meningitidi
await
